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Abstract
Background:  The objective of this study was to analyze the clinical and management
characteristics of chronic obstructive pulmonary disease (COPD) in men and women, to determine
possible gender-associated differences between the two groups of patients.
Methods: An observational and descriptive epidemiological study (EPIDEPOC study). The study
included patients with stable COPD and aged ≥ 40 years, evaluated in primary care. Data were
collected relating to sociodemographic variables, clinical characteristics, quality of life (SF-12),
severity of disease and treatment. The results obtained in men and women were compared.
Results: A total of 10,711 patients (75.6% males and 24.4% females) were evaluated. Significant
differences were found between males and females in relation to the following parameters: age
(67.4 ± 9.2 years in men vs 66.1 ± 10.8 in women, p < 0.05), smoking (91.9% of the men were
smokers or ex-smokers vs 30% of the women), comorbidity (the frequency of hypertension,
diabetes, anxiety and depression was greater in women, while ischemic heart disease was more
common in men), mental component of quality of life (49.4 ± 10.3 in men vs 44.6 ± 11.9 in women,
p < 0.05) and severity of disease (56.5 ± 13.3% in men vs 60.7 ± 3.2 in women, p < 0.05). As regards
treatment, the percentage use of long-acting b2-adrenergic agonists, anticholinergic agents,
theophyllines and mucolytic agents was significant greater in men. The total annual cost of COPD
was greater in males than in females (1989.20 ± 2364.47 € vs 1724.53 ± 2106.90, p < 0.05).
Conclusion: The women with COPD evaluated in this study were younger, smoked less and have
more comorbidity, a poorer quality of life, and lesser disease severity than men with COPD.
However, they generated a lesser total annual cost of COPD than men.
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Background
In recent years there has been an increase in the incidence,
prevalence and mortality of chronic obstructive pulmo-
nary disease (COPD) in women [1,2]. Indeed, in some
countries such as the United States, Canada, the United
Kingdom or Finland, the absolute number of cases of the
disease, as well as the number of hospital admissions and
deaths, has been greater in women than in men [1,3-5].
This situation has developed despite the fact that classi-
cally COPD has been less probably diagnosed in women
than in men [6,7].
Recent evidences have found that males and females
might show a fenotipically different respond to tobacco
smoke, showing men more propensities to develop an
emphysema profile of the disease, while women could
show mainly more airway affectation. However, as COPD
is an inflammatory condition, a sexual dimorphism could
be responsible for the different immunological response
observed in the human being according to gender [8].
A recent study has shown that among patients with stable
COPD, the women smoke less, are comparatively
younger, and have less comorbidity than men with the
same degree of airways obstruction [9]. However, the
mentioned study has some limitations. Firstly, the
patients were recruited exclusively from pneumology clin-
ics, and thus possibly were not representative of the over-
all COPD population. Secondly, the female data could be
applied only to those cases of smoking-related COPD,
and not to those attributable to exposure to risk factors
other than smoking. Third, since women have greater
bronchial hyper-responsiveness than men [10], the exclu-
sion of patients with symptoms of asthma or with a posi-
tive bronchodilator response may have introduced bias in
the population.
The present study was made to evaluate the existence of
gender differences in the clinical expression, diagnosis
and management of COPD in a non-selected population
of patients with the disease, recruited in the primary care
setting.
Methods
Study design and population
This study forms part of the EPIDEPOC survey, an obser-
vational and descriptive, multicenter epidemiological
study conducted in the primary care setting to explore the
use of health care resources and assess the quality of life of
patients with stable COPD [11].
Patient recruitment and calculation of the sample size cor-
responded to that conducted in the EPIDEPOC study. For
calculation of sample size, a cluster design was used, con-
sidering 3 types of variables: health centers, physicians,
and medical records. As the health centers were consid-
ered to be homogeneous and representatives of the Span-
ish geographical population, the medical record was
chosen as the unit of study and the prescriber as the clus-
ter. A previous study in a large cohort of 1,510 primary
care patients found that the average annual cost per
patient varied widely, with an estimated standard devia-
tion of  3,407 [6]. Assuming a precision of  90, 5,505
medical records needed to be evaluated. If the effect of the
cluster design is also taken into account, i.e., the loss of
efficacy from the use of clusters, assuming a correlation of
0.3 and a cluster size of 5, a total of 2,422 prescribers and
12,111 medical records would be required. The subjects
were consecutively included by primary care physicians in
all the Spanish Autonomous Communities, with a distri-
bution proportional to the population in each Commu-
nity. The patients were recruited during a period of three
months (from January 1 to March 31, 2003).
The study included patients of either sex or aged over 40
years, with a diagnosis of COPD established at least 12
months before the start of the study. The diagnosis of
COPD was based on the criteria of the Spanish Society of
Pneumology and Chest Surgery (Sociedad Española de Neu-
mología y Cirugía Torácica, SEPAR) according to the forced
spirometric demonstration of a forced expiratory volume
in one second (FEV1) of less than 80% the corresponding
reference value, and a FEV1/forced vital capacity (FVC)
ratio of under 0.7 following bronchodilator testing. The
severity of COPD was classified into three groups accord-
ing to the FEV1: mild (FEV1: 60–80% of the reference
value), moderate (FEV1: 40–59% of the reference value),
and severe (FEV1: less than 40% of the reference value),
based on the criteria of the SEPAR [12].
Patients with neurological or psychiatric disease not
allowing adequate evaluation at the time of the study were
excluded. Patients with COPD exacerbation in the previ-
ous month were likewise excluded. Exacerbation was
defined as worsening of the clinical condition of the
patient, in the form of increased expectoration, purulent
sputum production, increased baseline dyspnea, or any
combination of these symptoms.
The study was approved by the ethics committee of the
Fundación Hospital Alcorcón, and verbal informed consent
was obtained in all cases.
Evaluation of the patients
A single visit was made, in all cases documenting the soci-
odemographic parameters (including gender), the year of
diagnosis of COPD, the severity of the disease, and the use
of health care resources in the previous 12 months. Asso-
ciated comorbidity was also recorded, including the pres-
ence or absence of diabetes mellitus. The SF-12 quality ofBMC Pulmonary Medicine 2009, 9:2 http://www.biomedcentral.com/1471-2466/9/2
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life questionnaire (an abridged 12-item version of the SF-
36) was administered to all patients [13]. These 12 items
explain more than 90% of the variance of the physical and
mental components of the SF-36. They can be applied to
calculate two scores: physical (PCS-12) and mental (MCS-
12), using a value of 50 with a standard deviation (SD) of
10 as reference population. The SF-12 scores from 0 to
100, where the higher the score, the better the patient
health condition.
The direct costs were calculated from the information
relating to the different procedures, supplied by the man-
agement authorities of Area 8 Health Care (Madrid) and
of the Alcorcón and Móstoles Hospitals. The "human cap-
ital" method was used to compute the indirect costs. This
method uses as basic hypothesis the equivalence between
the value of lost production and the wage associated with
such production. In other words, one day off work implies
a production loss equivalent to the wage corresponding to
that same day. The data on employment and wages was
obtained from the Spanish National Statistical Institute
(Instituto Nacional de Estadística, INE) [14].
Statistical particulars
The SPSS version 12.0 statistical package for Microsoft
Windows was used throughout. Qualitative variables are
given as frequencies and percentages, and quantitative
variables as mean, standard deviation, minimum and
maximum values. The Pearson χ2 test was used to analyze
the relationship between qualitative variables. Normality
(Kolmogorov-Smirnov test), has been evaluated for all the
quantitative variables. If the variables did fit the normality
the Student t-test or ANOVA test for independent meas-
ures was used to calculate the differences between the
means of two or more groups in the bi-variant analysis. If
the normality could not be assumed nonparametric meth-
ods (Mann-Whitney U test or Kruskal-Wallism test) were
used.
Finally in order to control the confounding effect of co-
variables all comparisons between males and females
have been conducted using multivariate models (logistic
regression for binary variables and multiple lineal regres-
sion models for continuous variables). In all such cases
age and severity of were included as possible confounders.
Unfortunately the information about the physician who
collected the 5 patients was not included in the database.
Therefore we could not analyse the data using logistic
regression with random effects. Statistical significance was
accepted for p < 0.05.
Results
A total of 10,711 patients (75.6% males and 24.4%
females) were evaluated. The mean age was 67.1 ± 9.66
years, and was significantly greater in the male subgroup
than among the women (67.40 ± 9.20 vs 66.13 ± 10.82, p
< 0.05). Statistically significant differences were also seen
between males and females as refers to smoking. In the
male subgroup, 8.1% were non-smokers, 70.6% were ex-
smokers, and 21.3% were active smokers. In the female
subgroup, 70% were non-smokers, 17.7% were ex-smok-
ers, and 12.3% were active smokers. Table 1 shows the
sociodemographic characteristics of the study population
according to gender and smoking habit.
The mean FEV1 was 57.4 ± 13.4%. The degree of airways
obstruction was significantly greater in men than in
women (56.64 ± 13.35% vs 60.72 ± 13.26%, p < 0.05). As
regards comorbidity, the women showed a higher fre-
quency of hypertension (49.5% vs 47.1% in men, p <
0.05), diabetes mellitus (18.4% vs 16.4%, p < 0.05), anx-
iety (36.7% vs 17.6%, p < 0.05), depression (23.1% vs
9.5%, p < 0.05) and allergy (13.2% vs 5.7%, p < 0.05). In
Table 1: Sociodemographic characteristics of the studied COPD patients, according to gender and smoking habit.
VARIABLE Male non-smokers Male smokers Female non-smokers Female smokers
Age (mean ± SD) + †  (647) 66.99 ± 10.06 (7356) 67.47 ± 9.13 (1803) 68.58 ± 10.08 (773) 60.21 ± 10.26
Occupational status:
- Inactive (%) (440) 73.9 (5184) 77.6 (1417) 84.7 (428) 58.9
- Active (%) + †  (155) 26.0 (1494) 22.4 (256) 15.3 (298) 41.0
Educational level:
- Patients without basic schooling (%) (77) 14.7 (1142) 18.3 (536) 35.4 (85) 13.2
- Primary (%) (308) 58.7 (3630) 58.1 (812) 53.7 (304) 47.1
- Secondary (%) (103) 19.6 (1151) 18.4 (138) 9.1 (178) 27.6
- University (%) + †  (37) 7.0 (326) 5.2 (27) 1.8 (79) 12.2
* Significant difference in the comparison of male smokers versus male non-smokers.
+ Significant difference in the comparison of female smokers versus female non-smokers.
† Significant difference in the comparison of male smokers versus female smokers.
 Significant difference in the comparison of male non-smokers versus female non-smokers.BMC Pulmonary Medicine 2009, 9:2 http://www.biomedcentral.com/1471-2466/9/2
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contrast, males showed a comparatively higher frequency
of heart disease (19.6% vs 16.3% in women, p < 0.05) and
peptic ulcer (18.8% vs 12.7%, p < 0.05). As to health-
related quality of life, after adjusting by age and severity,
there were no significant gender differences in the scores
corresponding to the physical component (35.96 ± 9.94
in men vs 35.91 ± 9.91 in women), though the gender dif-
ferences were significant in the case of the mental compo-
nent (49.41 ± 10.33 in men vs 44.66 ± 11.97 in women).
Table 2 reports the health profile, the severity of airways
obstruction, comorbidity, and quality of life of the stud-
ied COPD patients, according to gender and smoking.
The men received a larger number of drugs for COPD than
the women. Thus, men used an average of 2.32 ± 1.03
drugs, compared with 2.17 ± 1.04 in the case of the
women – the difference being statistically significant.
Likewise significantly greater among males was the per-
centage use of long-acting b2-adrenergic agonists (9.8% vs
7.9% in females, p < 0.05), anticholinergic drugs (85.6%
vs 82.4%, p < 0.05), theophyllines (13.2% vs 7.6%, p <
0.05) and mucolytic agents (9.3% vs 7.7%, p < 0.05).
However, no gender differences were recorded in the fre-
quency of administration of corticoids – both inhalatory
(22.1% in males vs 22.2% in females) and oral (4.4% vs
5.3%). As to vaccination antecedents, men received the
antiinfluenza vaccine during the last campaign more
often than women (88.1% vs 84.7%, p < 0.05). Table 3
reports the drug treatment and vaccinations of the study
population according to gender and smoking habit.
Utilization of ressources in the last year was greater among
male smokers than in male non-smokers. Differences
were also detected in the number of primary care visits
between male and female smokers (Table 4).
The total annual cost of COPD management per patient
was greater in males than in females (1989.20 ± 2364.47
vs 1724.53 ± 2106.90  , p < 0.05). Differences were like-
wise detected between male smokers and female smokers
(2023.29 ± 2384.22   vs 1696.15 ± 2165.94  , p < 0.05).
Table 5 shows the cost of the different health care
resources utilized by the COPD patients according to gen-
der and smoking habit.
Table 2: Health profile, severity of airways obstruction according to FEV1, co-morbidity, and quality of life (generic SF-12 
questionnaire) of the studied COPD patients, according to gender and smoking habit.
Parameter Male non-smokers Male smokers Female non-smokers Female smokers
Physical exercise: * † 
- None (%) (153) 21.9 (2233) 30.6 (758) 42.5 (232) 30.4
- Light (%) (436) 68.1 (4735) 64.8 (981) 55.0 (474) 62.0
- Moderate (%) (51) 8.0 (334) 4.6 (43) 2.4 (58) 7.6
Obesity: + † 
- Normal weight (%) (130) 20.6 (1616) 22.3 (445) 25.6 (279) 36.6
- Overweight (%) (382) 60.6 (4130) 57.0 (786) 45.2 (342) 44.8
- Obese (%) (118) 18.7 (1489) 20.6 (509) 29.2 (142) 18.6
Severity of obstruction (according to FEV1) * + †
Mild (270) 44.1 (2276) 32.2 (695) 40.7 (342) 46.4
Moderate (296) 48.4 (3906) 55.2 (861) 50.5 (353) 47.9
Severe (46) 7.5 (896) 12.7 (150) 8.8 (42) 5.7
Comorbidity:
- Hypertension (%) * + †  (229) 40.0 (3259) 47.8 (899) 53.8 (277) 39.3
- Hypercholesterolemia (%) * (197) 35.2 (2833) 42.3 (668) 41.0 (262) 38.0
- Heart disease (%) + † (84) 15.4 (1294) 19.9 (301) 18.9 (65) 9.8
- Gastroduodenal ulcer (%) * † (75) 13.7 (1254) 19.2 (207) 13.1 (78) 11.7
- Depression (%) †  (46) 8.5 (619) 9.6 (353) 22.2 (168) 25.2
- Anxiety (%) †  (89) 16.2 (1145) 17.7 (568) 35.6 (264) 39.4
- Diabetes(%) +  (71) 13.0 (1089) 16.7 (322) 20.1 (96) 14.4
SF12 mental component (mean ± SD) †  (647) 50.3 ± 9.8 (7356) 49.3 ± 10.4 (1803) 44.5 ± 12.0 (773) 44.9 ± 12.1
SF12 physical component (mean ± SD) * + †  (647) 38.1 ± 10.0 (7356) 35.8 ± 9.9 (1803) 34.6 ± 9.6 (773) 38.9 ± 9.8
Normal weight (BMI < 27), Overweight (BMI ≥ 27 < 30), Obesity (BMI ≥ 30).
* Significant difference in the comparison of male smokers versus male non-smokers.
+ Significant difference in the comparison of female smokers versus female non-smokers.
† Significant difference in the comparison of male smokers versus female smokers, after adjusting by age and severity
 Significant difference in the comparison of male non-smokers versus female non-smokers, after adjusting by age and severity.BMC Pulmonary Medicine 2009, 9:2 http://www.biomedcentral.com/1471-2466/9/2
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Discussion
The main finding of this study is that there are differences
in the sociodemographic characteristics, associated dis-
eases, quality of life, treatment, utilization of resources
and cost of COPD according to patient gender and smok-
ing habit. The true strength of the survey is found in the
large number of patients involved, and in the fact that
these were real-life subjects not included in a clinical trial
but recruited in the primary care setting.
A number of previous studies have reported gender differ-
ences in the clinical presentation, diagnosis, treatment
and prognosis of COPD [15-20]. Thus, it has been shown
that women have more respiratory symptoms than men,
with increased airways responsiveness, lower quality of
life questionnaire scores, lesser response to prolonged
treatment with exercise, and a more favorable prognosis at
the time of starting oxygen therapy.
Of note in the present study is the large proportion of
non-smoking women. No evaluation has been made of
passive exposure to tobacco smoke, though women are
known to be more exposed, and are more sensitive to
exposure, than men [21]. In any case, earlier studies have
shown the implication of other risk factors in the patho-
genesis of COPD, including genetic factors, infections,
environmental pollution, and occupational exposure
[22]. Thus, as an example, a recent study has demon-
strated a relationship between exposure to the smoke of
burning wood or coal and the development of COPD
[23]. The fact that our patients had been diagnosed with
COPD for one year and presented spirometric evidence of
airways obstruction upon inclusion in the study, increases
the reliability of our findings. Another possibility is that a
proportion of the non-smoking women in our series may
actually not have COPD but other disorders characterized
by airways obstruction, such as asthma. In fact, the per-
centage of an allergy history was higher in the female
group. In this sense, no bronchodilator tests were carried
out in this study, though it has been shown that unless full
obstruction reversion is achieved, the mentioned test
shows poor performance in discriminating between
COPD and asthma [24]. In any case, the balance of error
tends to tip in the opposite direction, i.e., it is more com-
mon to diagnose women with respiratory symptoms of
asthma than of COPD [20,25], in the same way as among
non-smokers [26]. On the other hand, and as has been
commented above, in the evaluation of the clinical
course, the subjects with asthma features were excluded;
as a result, the impact of asthma upon the end results is
scantly relevant.
Table 3: Drug treatment and vaccinations of the studied COPD patients, according to gender and smoking habit.
Treatment Male non-smokers Male smokers Female non-smokers Female smokers
Short-acting β2-adrenergic agonists (%)* (216) 33.4 (2927) 39.8 (685) 38.0 (289) 37.4
Long-acting β2-adrenergic agonists (%) (53) 8.2 (735) 10.0 (149) 8.3 (55) 7.1
Anticholinergic agents (%)† (549) 84.8 (6304) 85.7 (1489) 82.6 (635) 82.1
Theophyllines (%)† (64) 9.9 (986) 13.4 (155) 8.6 (42) 5.4
Inhalatory corticoids (%)+† (123) 19.0 (1648) 22.4 (441) 24.4 (130) 16.8
Oral corticoids (%) (27) 4.2 (331) 4.5 (105) 5.8 (31) 4.0
Mucolytic agents (%)† (50) 7.7 (692) 9.4 (151) 8.4 (48) 6.2
Antiinfluenza vaccine in last campaign (%)+† (547) 85.3 (6409) 88.3 (1585) 88.9 (568) 74.8
Antipneumococcal vaccination at some time in past (%)+† (210) 33.5 (2332) 32.8 (618) 35.5 (150) 20.2
* Significant difference in the comparison of male smokers versus male non-smokers.
+ Significant difference in the comparison of female smokers versus female non-smokers.
† Significant difference in the comparison of male smokers versus female smokers, after adjusting by age and severity
 Significant difference in the comparison of male non-smokers versus female non-smokers, after adjusting by age and severity.
Table 4: Utilization of health care resources in the previous year among the COPD patients according to gender and smoking habit.
Health care resources Male non-smokers Male smokers Female non-smokers Female smokers
No. visits to primary care * †  (625) 5.91 ± 5.67 (7045) 6.77 ± 5.75 (1724) 6.69 ± 5.72 (731) 6.18 ± 5.30
No. visits to pneumology clinic * (602) 1.30 ± 1.53 (6838) 1.47 ± 1.54 (1640) 1.37 ± 1.40 (706) 1.32 ± 1.59
No. visits to emergency service *  (581) 1.70 ± 0.81 (6608) 1.90 ± 0.87 (1592) 1.84 ± 0.86 (684) 1.84 ± 0.89
No. hospital admissions * (523) 0.36 ± 0.83 (6026) 0.54 ± 1.27 (1429) 0.44 ± 0.93 (598) 0.41 ± 0.94
Duration hospital stay (days) * (262) 5.74 ± 10.49 (3325) 7.67 ± 11.54 (773) 6.26 ± 10.37 (335) 6.27 ± 14.00
* Significant difference in the comparison of male smokers versus male non-smokers.
+ Significant difference in the comparison of female smokers versus female non-smokers.
† Significant difference in the comparison of male smokers versus female smokers, after adjusting by age and severity.
 Significant difference in the comparison of male non-smokers versus female non-smokers, after adjusting by age and severity.BMC Pulmonary Medicine 2009, 9:2 http://www.biomedcentral.com/1471-2466/9/2
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Some studies suggest that women are more susceptible to
the deleterious effects of smoking. A number of publica-
tions suggest that women have lung function similar to
that of males at a younger age and with a lesser smoking
history [9,27-32]. Gender-associated differences have also
been found in the gradual worsening of lung function in
smokers with COPD [33]. Thus, the annual decline in
lung function in women has been associated with the
degree of airways obstruction – an effect not seen in
males.
Some authors report that women have fewer associated
diseases than males with the same degree of airways
obstruction [9]. In this study it has been shown that in
general hypertension and diabetes mellitus is more com-
mon in women, while men show a larger proportion of
other disorders such as hypercholesterolemia and
ischemic heart disease – with differences in both cases
according to smoking status. In addition, anxiety and
depression were more frequent in women. Di Marco et al.
also observed that women with COPD appear to be more
exposed to psychological problems – these being related
to symptomatic aspects of the disease such as dyspnea
[34]. Lastly, and in coincidence with earlier studies report-
ing gender-associated differences in atopic markers [35-
37], we recorded an increased allergy history in women
compared with men. Other authors have published simi-
lar results [38,39].
As regards treatment, earlier studies have reported an
increased frequency of inhalatory corticoid use among
women, with a comparatively lower percentage use of the-
ophyllines [40]. We likewise observed a lesser percentage
use of theophyllines among women than in men – possi-
bly in relation to the lesser severity of airways obstruction
among the former. In relation to oxygen therapy, it has
been shown that the mortality risk among COPD patients
administered such therapy is greater in women than in
men [41]. An explanation for such a poorer prognosis
among women could be that the systemic complications
of COPD, such as muscle dysfunction or depression, are
more frequent in women and involve a poorer patient
course [42].
Gender-associated differences were also observed in utili-
zation of health resources. In fact, women have been
shown to make more frequent utilization of health care
services than men [43]. It also has been suggested that the
risk for hospital admission is greater among women, and
that the number of admissions due to COPD will gradu-
ally increase among females in the coming years [43,44].
In our study, gender differences were seen in the fre-
quency of visits to the primary care physician – with more
frequent visits among male smokers than in female smok-
ers – and in the number of visits to the emergency service
(greater in non-smoking women than in non-smoking
men).
As refers to health-related quality of life, some authors
have found that, for one same FEV1 level, women yield
poorer scores in all domains of the St. George question-
naire [9]. In addition, the factors associated to quality of
life have been shown to vary between sexes. Thus, in
males, the main predictors include dyspnea, exercise
capacity, the degree of hyper-insufflation, and comorbid-
ity – while in women the main predictors are dyspnea and
arterial oxygenation [45]. Other studies have reported
poorer scores in the quality of life questionnaires in
women compared with men [16-34,46-49]. In our study,
women yielded lower scores in the mental component of
quality of life, but not in the physical dimension. How-
ever, gender differences were obtained in this parameter
according to patient smoker status. As regards the finan-
cial factors, we found the costs associated with COPD to
be generally higher in males – particularly among the
smokers. In contrast, other studies have reported no gen-
Table 5: Cost of health care resources utilized among the COPD patients according to gender and smoking habit.
Cost component Male non-smokers Male smokers Female non-smokers Female smokers
Visits to primary care physician (€) * †  (647) 95.77 ± 95.17 (7356) 108.81 ± 97.16 (1803) 107.25 ± 96.68 (773) 97.92 ± 89.58
Visits to pneumologist (€) † (647) 85.35 ± 107.16 (7356) 96.44 ± 108.63 (1803) 88.01 ± 98.77 (773) 85.21 ± 110.45
Visits to emergency service (€) *  (647) 101.45 ± 158.97 (7356) 139.67 ± 199.43 (1803) 125.73 ± 179.95 (773) 129.12 ± 209.41
Hospital admission (€) * † (647) 584.04 ± 1532.18 (7356) 849.24 ± 1827.62 (1803) 685.60 ± 1598.17 (773) 642.26 ± 1702.83
Diagnostic tests (€) † (647) 117.77 ± 147.87 (7356) 133.08 ± 149.89 (1803) 121.44 ± 136.29 (773) 117.58 ± 152.41
Respiratory drugs (€) † (647) 471.97 ± 401.21 (7356) 502.24 ± 415.07 (1803) 477.62 ± 409.10 (773) 443.92 ± 387.19
Oxygen therapy (€) * † (647) 54.72 ± 223.56 (7356) 105.88 ± 312.46 (1803) 77.00 ± 271.35 (773) 48,93 ± 219.68
Sick leave (€) + † (647) 56.81 ± 280.13 (7356) 70.16 ± 291.70 (1803) 35.39 ± 205.88 (773) 118.63 ± 339.38
Antiinfluenza vaccination (€) + † (647) 0.18 ± 0.55 (7356) 0.20 ± 0.58 (1803) 0.17 ± 0.54 (773) 0.37 ± 0.75
Antipneumococcal vaccination (€) + † (647) 4.76 ± 6.87 (7356) 4.65 ± 6.83 (1803) 5.03 ± 6.96 (773) 2.84 ± 5.80
Total annual cost per COPD patient (€) * † (647) 1585.93 ± 2085.04 (7356) 2023.29 ± 2384.22 (1803) 1736.78 ± 2078.85 (773) 1696.15 ± 2165.94
* Significant difference in the comparison of male smokers versus male non-smokers.
+ Significant difference in the comparison of female smokers versus female non-smokers.
† Significant difference in the comparison of male smokers versus female smokers, after adjusting by age and severity.
 Significant difference in the comparison of male non-smokers versus female non-smokers, after adjusting by age and severity.BMC Pulmonary Medicine 2009, 9:2 http://www.biomedcentral.com/1471-2466/9/2
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der-associated differences in the costs associated with this
disease [50]. These results should be taken into account
when designing specific treatment strategies for different
groups of COPD patients.
A possible limitation of our study is that, as commented
previously in the method section, we did not use logistic
regression with random effects. Ignoring clustering and
unequal probability of selection of participants in our
analyses may result in biased estimates [51,52].
Conclusion
In conclusion, there are gender-related differences in the
clinical characteristics, management, quality of life, and
costs of COPD. The women with COPD evaluated in this
study were younger, smoked less and have more comor-
bidity, a poorer quality of life and lesser disease severity
than men with COPD. In addition, they used fewer drugs
and health care resources than males – though there were
also differences between the two gender groups according
to smoker status.
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